Skip to main content
Top
Published in: Journal of Urban Health 4/2010

Open Access 01-07-2010

Three Years after Legalization of Nonprescription Pharmacy Syringe Sales in California: Where Are We Now?

Authors: Richard S. Garfein, PhD, MPH, Thomas J. Stopka, Patricia B. Pavlinac, Alessandra Ross, B. Karen Haye, Elise D. Riley, Ricky N. Bluthenthal

Published in: Journal of Urban Health | Issue 4/2010

Login to get access

Abstract

In January 2005, passage of California Senate Bill 1159 enabled California’s county or city governments to establish disease prevention demonstration projects (DPDPs) through which pharmacies could subsequently register to legally sell up to 10 syringes to adults without a prescription. California’s 61 local health jurisdictions (LHJs) were surveyed annually in 2005–2007 to monitor the progress of DPDP implementation and assess program coverage, facilitators, and barriers. Completed surveys were returned by mail, fax, e-mail, phone, or internet. We analyzed 2007 survey data to describe current DPDP status; data from all years were analyzed for trends in approval and implementation status. By 2007, 17 (27.9%) LHJs approved DPDPs, of which 14 (82.4%) had registered 532 (17.8%) of the 2,987 pharmacies in these 14 LHJs. Although only three LHJs added DPDPs since 2006, the number of registered pharmacies increased 102% from 263 previously reported. Among the LHJs without approved DPDPs in 2007, one (2.3%) was in the approval process, seven (16.3%) planned to seek approval, and 35 (81.4%) reported no plans to seek approval. Of 35 LHJs not planning to seek approval, the top four reasons were: limited health department time (40%) or interest (34%), pharmacy disinterest (31%), and law enforcement opposition (26%). Among eight LHJs pursuing approval, the main barriers were “time management” (13%), educating stakeholders (13%), and enlisting pharmacy participation (13%). The17 LHJs with DPDP represent 52% of California’s residents; they included 62% of persons living with HIV and 59% of IDU-related HIV cases, suggesting that many LHJs with significant numbers of HIV cases have approved DPDPs. Outcome studies are needed to determine whether SB 1159 had the desired impact on increasing syringe access and reducing blood-borne viral infection risk among California IDUs.
Literature
3.
4.
go back to reference Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10): 705-714.PubMed Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10): 705-714.PubMed
5.
go back to reference Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001; 34(1): 180-187.CrossRefPubMed Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001; 34(1): 180-187.CrossRefPubMed
6.
go back to reference Tseng FC, O'Brien TR, Zhang M, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology. 2007; 46(3): 666-671.CrossRefPubMed Tseng FC, O'Brien TR, Zhang M, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology. 2007; 46(3): 666-671.CrossRefPubMed
7.
go back to reference Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009; 200(8): 1216-1226.CrossRefPubMed Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009; 200(8): 1216-1226.CrossRefPubMed
8.
go back to reference Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001; 91(1): 42-46.PubMed Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001; 91(1): 42-46.PubMed
9.
go back to reference Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med. 2008; 70(5): 606-611.CrossRefPubMed Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med. 2008; 70(5): 606-611.CrossRefPubMed
10.
go back to reference Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep. 1998; 113(Suppl 1): 75-80.PubMed Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep. 1998; 113(Suppl 1): 75-80.PubMed
11.
go back to reference Neaigus A, Zhao M, Gyarmathy VA, Cisek L, Friedman SR, Baxter RC. Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. J Urban Health. 2008; 85(3): 309-322.CrossRefPubMed Neaigus A, Zhao M, Gyarmathy VA, Cisek L, Friedman SR, Baxter RC. Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. J Urban Health. 2008; 85(3): 309-322.CrossRefPubMed
13.
go back to reference Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996; 86(5): 642-654.CrossRefPubMed Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996; 86(5): 642-654.CrossRefPubMed
14.
go back to reference Fuller CM, Galea S, Caceres W, Blaney S, Sisco S, Vlahov D. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health. 2007; 97(1): 117-124.CrossRefPubMed Fuller CM, Galea S, Caceres W, Blaney S, Sisco S, Vlahov D. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health. 2007; 97(1): 117-124.CrossRefPubMed
15.
go back to reference Pouget ER, Deren S, Fuller CM, et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. J Acquir Immune Defic Syndr. 2005; 39(4): 471-477.CrossRefPubMed Pouget ER, Deren S, Fuller CM, et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. J Acquir Immune Defic Syndr. 2005; 39(4): 471-477.CrossRefPubMed
17.
go back to reference Stopka TJ, Garfein RS, Ross A, Truax SR. Increasing syringe access and HIV prevention in California: findings from a survey of local health jurisdiction key personnel. J Urban Health. 2007; 84(1): 116-125.CrossRefPubMed Stopka TJ, Garfein RS, Ross A, Truax SR. Increasing syringe access and HIV prevention in California: findings from a survey of local health jurisdiction key personnel. J Urban Health. 2007; 84(1): 116-125.CrossRefPubMed
21.
go back to reference Bluthenthal RN, Heinzerling KG, Anderson R, Flynn NM, Kral AH. Approval of syringe exchange programs in California: results from a local approach to HIV prevention. Am J Public Health. 2008; 98(2): 278-283.CrossRefPubMed Bluthenthal RN, Heinzerling KG, Anderson R, Flynn NM, Kral AH. Approval of syringe exchange programs in California: results from a local approach to HIV prevention. Am J Public Health. 2008; 98(2): 278-283.CrossRefPubMed
22.
go back to reference Cooper E, Dodson C, Stopka TJ, Riley ED, Garfein RS, Bluthenthal RN. Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco Counties, 2007. J Urban Health. 2010 (this issue). Cooper E, Dodson C, Stopka TJ, Riley ED, Garfein RS, Bluthenthal RN. Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco Counties, 2007. J Urban Health. 2010 (this issue).
23.
go back to reference Cotten-Oldenburg NU, Carr P, DeBoer JM, Collison EK, Novotny G. Impact of pharmacy-based syringe access on injection practices among injecting drug users in Minnesota, 1998 to 1999. J Acquir Immune Defic Syndr. 2001; 27(2): 183-192.PubMed Cotten-Oldenburg NU, Carr P, DeBoer JM, Collison EK, Novotny G. Impact of pharmacy-based syringe access on injection practices among injecting drug users in Minnesota, 1998 to 1999. J Acquir Immune Defic Syndr. 2001; 27(2): 183-192.PubMed
24.
go back to reference Rich JD, Hogan JW, Wolf F, et al. Lower syringe sharing and re-use after syringe legalization in Rhode Island. Drug Alcohol Depend. 2007; 89(2–3): 292-297.CrossRefPubMed Rich JD, Hogan JW, Wolf F, et al. Lower syringe sharing and re-use after syringe legalization in Rhode Island. Drug Alcohol Depend. 2007; 89(2–3): 292-297.CrossRefPubMed
25.
go back to reference Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006; 41(6–7): 777-813.CrossRefPubMed Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006; 41(6–7): 777-813.CrossRefPubMed
26.
go back to reference Friedman SR, Perlis T, Des Jarlais DC. Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence. Am J Public Health. 2001; 91(5): 791-793.CrossRefPubMed Friedman SR, Perlis T, Des Jarlais DC. Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence. Am J Public Health. 2001; 91(5): 791-793.CrossRefPubMed
27.
go back to reference Compton WM 3rd, Cottler LB, Decker SH, Mager D, Stringfellow R. Legal needle buying in St. Louis. Am J Public Health. 1992; 82(4): 595-596.CrossRefPubMed Compton WM 3rd, Cottler LB, Decker SH, Mager D, Stringfellow R. Legal needle buying in St. Louis. Am J Public Health. 1992; 82(4): 595-596.CrossRefPubMed
28.
go back to reference Lewis BA, Koester SK, Bush TW. Pharmacists’ attitudes and concerns regarding syringe sales to injection drug users in Denver, Colorado. J Am Pharm Assoc (Wash). 2002; 42(6 Suppl 2): S46-S51.CrossRef Lewis BA, Koester SK, Bush TW. Pharmacists’ attitudes and concerns regarding syringe sales to injection drug users in Denver, Colorado. J Am Pharm Assoc (Wash). 2002; 42(6 Suppl 2): S46-S51.CrossRef
29.
go back to reference Taussig J, Junge B, Burris S, Jones TS, Sterk CE. Individual and structural influences shaping pharmacists’ decisions to sell syringes to injection drug users in Atlanta, Georgia. J Am Pharm Assoc (Wash). 2002; 42(6 Suppl 2): S40-S45.CrossRef Taussig J, Junge B, Burris S, Jones TS, Sterk CE. Individual and structural influences shaping pharmacists’ decisions to sell syringes to injection drug users in Atlanta, Georgia. J Am Pharm Assoc (Wash). 2002; 42(6 Suppl 2): S40-S45.CrossRef
30.
go back to reference Coffin PO, Linas BP, Factor SH, Vlahov D. New York City pharmacists' attitudes toward sale of needles/syringes to injection drug users before implementation of law expanding syringe access. J Urban Health. 2000; 77(4): 781-793.CrossRefPubMed Coffin PO, Linas BP, Factor SH, Vlahov D. New York City pharmacists' attitudes toward sale of needles/syringes to injection drug users before implementation of law expanding syringe access. J Urban Health. 2000; 77(4): 781-793.CrossRefPubMed
31.
go back to reference Riley ED, Kral A, Stopka TJ, Garfein RS, Reuckhaus P, Bluthenthal RN. Access to sterile syringes through San Francisco pharmacies and the association with HIV risk behavior among injection drug users. J Urban Health. 2010 (this issue). Riley ED, Kral A, Stopka TJ, Garfein RS, Reuckhaus P, Bluthenthal RN. Access to sterile syringes through San Francisco pharmacies and the association with HIV risk behavior among injection drug users. J Urban Health. 2010 (this issue).
32.
go back to reference McNeely J, Arnsten JH, Gourevitch MN. Sterile syringe access and disposal among injection drug users newly enrolled in methadone maintenance treatment: a cross-sectional survey. Harm Reduct J. 2006; 3: 8.CrossRefPubMed McNeely J, Arnsten JH, Gourevitch MN. Sterile syringe access and disposal among injection drug users newly enrolled in methadone maintenance treatment: a cross-sectional survey. Harm Reduct J. 2006; 3: 8.CrossRefPubMed
Metadata
Title
Three Years after Legalization of Nonprescription Pharmacy Syringe Sales in California: Where Are We Now?
Authors
Richard S. Garfein, PhD, MPH
Thomas J. Stopka
Patricia B. Pavlinac
Alessandra Ross
B. Karen Haye
Elise D. Riley
Ricky N. Bluthenthal
Publication date
01-07-2010
Publisher
Springer US
Published in
Journal of Urban Health / Issue 4/2010
Print ISSN: 1099-3460
Electronic ISSN: 1468-2869
DOI
https://doi.org/10.1007/s11524-010-9463-3

Other articles of this Issue 4/2010

Journal of Urban Health 4/2010 Go to the issue